Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178533
Title: | Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma |
Author: | Robak, Tadeusz Huang, Huiqiang Jin, Jie Zhu, Jun Liu, Ting Samoilova, Olga Pylypenko, Halyna Verhoef, Gregor Siritanaratkul, Noppadol Osmanov, Evgenii Alexeeva, Julia Pereira, Juliana Drach, Johannes Mayer, Jiří Hong, Xiaonan Okamoto, Rumiko Pei, Lixia Rooney, Brendan Van de Velde, Helgi Cavalli, Franco González Barca, Eva LYM-3002 Investigators |
Keywords: | Medicaments antineoplàstics Limfomes Ús terapèutic Antineoplastic agents Lymphomas Therapeutic use |
Issue Date: | 5-Mar-2015 |
Publisher: | Massachusetts Medical Society |
Abstract: | Background: the proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. Methods: in this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. Results: after a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Conclusions: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137). |
Note: | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1412096 |
It is part of: | New England Journal of Medicine, 2015, vol. 372, num. 10, p. 944-953 |
URI: | http://hdl.handle.net/2445/178533 |
Related resource: | https://doi.org/10.1056/NEJMoa1412096 |
ISSN: | 0028-4793 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
679862.pdf | 391.52 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.